Bone Medical

Bone Medical Limited, a biopharmaceutical company, focusessed on the development of medicines for the treatment of musculoskeletal diseases, primarily osteoporosis, osteoarthritis, and rheumatoid arthritis. The company developed Capsitonin, an oral calcitonin that was in Phase II clinical trial for the treatment of osteoporosis and osteoarthritis pain; and CaPTHymone, an oral parathyroid hormone, which was in Phase II clinical trial for the treatment of osteoporosis. In July 2016 the company changed its name to Botanix Pharmaceuticals Limited after the completion of the acquisition of Botanix Pharmaceuticals in a reverse takeover deal.